8-K: Quantum-Si Unveils Proteus Platform, 2026 Launch

Quantum-Si Incorporated detailed its next-generation Proteus platform, long-term technology roadmap, and plans for a 2026 commercial launch at its Investor & Analyst Day.

Summary

• Quantum-Si presented its Proteus platform, a next-generation single-molecule protein sequencing system, at its Investor & Analyst Day on November 19, 2025.
• The Proteus system, featuring the KinetIQ Array with 80 million wells, is designed to offer significant improvements over the current Platinum Pro system, including enhanced sequencing output, longer alignments, and superior signal-to-noise ratio.
• The company is on track to achieve detection of 18 amino acids at Proteus launch in 2026, with a goal of all 20 canonical amino acids by 2027, utilizing advanced recognizer development and AI models.
• Proteus will enable broad post-translational modification (PTM) analysis through kinetic, pre-recognition, and direct N-terminal detection methods, crucial for understanding disease mechanisms.
• Key technical risks for Proteus have been retired, and the integrated system design is complete, with the first systems currently being built.
• The company is shifting its commercial strategy to focus on defined, high-value applications and is building a partner ecosystem for sample preparation, application development, and AI-driven data analysis.
• New partnerships include Carna Biosciences for kinase phosphorylation profiling and Siena Quant for ultra-low-abundance biomarker panels.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook on the company's technological advancements, particularly with the Proteus platform. It highlights significant improvements over previous technology, successful de-risking of key components, a clear roadmap for future capabilities (20 amino acids, PTMs, billions of reads), and strategic partnerships. The detailed milestones leading to a Q4 2026 launch indicate strong execution and confidence. While no financial metrics are provided, the technological progress and market expansion strategy are very encouraging.

Positives

• Proteus architecture shows significant improvement over Platinum in quantity and quality of sequencing output, including more alignments, longer reads, and better SNR.
• Successful dynamic sequencing runs completed in Q3, substantially de-risking new system elements like consumables, dyes, optics, and software.
• KinetIQ Array fabrication and post-processing processes are established, with optimized well structure and efficient packaging.
• Demonstrated detection of 18 amino acids, with campaigns for C and T underway, aiming for all 20 canonical amino acids by 2027.
• Successfully demonstrated a controlled cleavage version of sequencing chemistry, enabling faster time/residue and a scanning system for future platforms.
• Proteus automation greatly simplifies the sequencing workflow, reducing manual steps from over 100 to a single reagent module and cartridge loading.
• New industry partnerships with Carna Biosciences and Siena Quant are expected to accelerate application development and deliver sample-to-report workflows.
• The Proteus platform is expected to enable single-molecule protein sequencing across a broad range of end markets, including academic research, pharma, biotech, clinical diagnostics, and agriculture.

Negatives

• Current Platinum Pro system has limitations in adoption outside core labs due to high capital costs (>$1M per instrument) and manual workflows.
• The current sequencing chemistry involves random cutting and non-uniform residue duration, which is slower on average compared to the future controlled cutting method.
• The current V4 Sequencing Kit only recognizes 14 of 20 amino acids, requiring further development to achieve full coverage.
• Mass spectrometry and affinity-based platforms, while existing, have challenges in PTM quantification, site assignment ambiguity, and workflow complexity, which Proteus aims to overcome.

Risks

• The successful execution of the development roadmap to deliver a compelling Proteus launch by Q4 2026.
• The ability to scale recognizer development to achieve detection of all 20 canonical amino acids and release on Proteus in 2027.
• The successful integration of artificial intelligence for data analysis to fully extract kinetic information for PTM and variant detection.
• The ability to build and leverage a partner ecosystem to accelerate application development and deliver sample-to-report workflows.
• Market adoption of the new Proteus platform, especially in expanding beyond core labs to translational and clinical settings.

Future Outlook

Quantum-Si anticipates the commercial launch of its Proteus platform in Q4 2026, with fully integrated systems operational by Q1 2026. The company aims to achieve detection of all 20 canonical amino acids by 2026, with a release on Proteus in 2027, and will continue to develop broad PTM analysis solutions. Future technology roadmaps include scaling to billions of reads with Proteus 2.0, incorporating controlled cleavage chemistry and high-speed scanning. The company plans to expand its market penetration in academic medical centers and other end markets through high-value applications, increased throughput, and strategic partnerships.

Management Comments

• Proteins Are the Core of Biological Discoveries Across Many End Markets.
• Only single-molecule protein sequencing can tackle this complexity [of proteoforms].
• Proteus will enable deep protein analysis and accelerate the field of proteomics.
• Transition to new architecture is proven – team is executing towards product launch for YE2026.
• Proteus architecture shows significant improvement over Platinum in the quantity and quality of sequencing output.
• Proteus sequencing performance is on track to far exceed Platinum at launch.
• Recognizer development program is being scaled to achieve detection of all canonical amino acids in 2026 and release on Proteus in 2027.
• QSI is well-positioned to build upon our first-to-market advantage and extend our leadership into the future.

Industry Context

The proteomics field is characterized by the immense complexity of proteoforms, which are critical for understanding disease but challenging to study with existing technologies like mass spectrometry and affinity-based platforms. Current specialized platforms often involve high capital costs (over $1M per instrument) and manual workflows, limiting adoption outside core labs. Quantum-Si's Proteus platform aims to address these limitations by offering an affordable, automated, single-molecule protein sequencing solution that can provide deep protein analysis, broad PTM coverage, and single amino acid variant detection, thereby accelerating the field and expanding access to proteomics beyond specialized core labs.

Comparison to Industry Standards

• Current specialized proteomics platforms often cost $1M or more each, limiting adoption, whereas Proteus aims to be affordable for 'any lab, anywhere.'
• Existing affinity-based methods cannot scale to the complexity of proteoforms, requiring hundreds of thousands of site-specific reagents, while single-molecule protein sequencing is presented as the most versatile technology.
• Mass spectrometry faces challenges with PTM quantification, ambiguity in modification site assignment, and workflow complexity, which Proteus's single-molecule detection aims to overcome with direct counting and site identification.
• Proteus is positioned to offer superior sequencing output per well, longer alignments, and better signal-to-noise ratio compared to Quantum-Si's own previous Platinum platform.
• The automation of Proteus significantly simplifies laboratory workflow compared to manual processes common in current proteomics labs, which can involve over 100 pipetting steps per sample.

Stakeholder Impact

• Shareholders: Potential for increased value due to advanced technology, expanded market reach, and strategic partnerships. The successful launch of Proteus could drive significant growth.
• Customers (Researchers, Pharma/Biotech, Clinical Labs): Access to a more affordable, automated, and powerful single-molecule protein sequencing platform, enabling deeper insights into proteoforms, PTMs, and variants, accelerating biological discoveries and drug development.
• Employees: Continued focus on R&D innovation and execution, potentially leading to growth opportunities within the company.
• Suppliers: Potential for increased demand for components and services related to the Proteus platform and KinetIQ Array.
• Creditors: Improved financial health and growth prospects could enhance creditworthiness.

Next Steps

• Demonstrate 20 amino acid detection (Q4 2025).
• Deliver and make operational fully integrated Proteus systems (Q1 2026).
• Conduct end-to-end sequencing on fully integrated systems (Q2 2026).
• Release instrument list price (Q2 2026).
• Release Platinum upgrade program (Q3 2026).
• Release Proteus launch capabilities (Q3 2026).
• Initiate external customer collaborations (Summer 2026).
• Complete internal V&V (Q4 2026).
• Commercial launch of Proteus (Q4 2026).
• Achieve detection of all 20 canonical amino acids (2026).
• Release 20 amino acid detection on Proteus (2027).
• Continue to build a partner ecosystem to accelerate application development and deliver sample-to-report workflows.
• Grow user base with Platinum Pro and develop the market for Proteus launch.

Key Dates

Recommendation

The filing details significant technological advancements with the Proteus platform, demonstrating superior performance over previous generations and addressing key limitations in the proteomics market. The clear roadmap for achieving full amino acid detection, comprehensive PTM analysis, and scaling to billions of reads positions Quantum-Si as a leader in single-molecule protein sequencing. Strategic partnerships and a focused commercial launch strategy for high-value applications further de-risk market adoption. The detailed milestones leading to a Q4 2026 launch, coupled with the retirement of key technical risks, indicate strong execution and a high probability of future success, making the stock a compelling 'strong buy' for long-term growth investors.

Keywords

Quantum-Si, Proteus, Protein Sequencing, Proteomics, SEC Filing, Investor Day, KinetIQ Array, Amino Acid Detection, PTM Analysis, Post-translational Modification, Biotechnology, Life Sciences, Financial Reporting, QSI, Single-Molecule Sequencing